A Phase I Dose-finding Trial of Hyperthermic Intraperitoneal Paclitaxel Combined With Cisplatin
Ovarian Cancer, Hyperthermic Intraperitoneal Chemotherapy, Paclitaxel
About this trial
This is an interventional treatment trial for Ovarian Cancer
Eligibility Criteria
Inclusion Criteria: age between 18 and 65 years; adequate renal function (blood creatinine: 58-96 µmol/L), bone marrow function (hemoglobin ≥ 110 g/L, white cell count ≥ 4.0 ×109/L, neutrophil count ≥ 2.0 × 109/L, platelet count ≥ 100 × 109/L) and hepatic function [bilirubin 3.4-22.2 µmol/L, alanine aminotransferase (ALT) 7-40 U/L, aspartate aminotransferase (AST) 13-35 U/L, AST/ALT≤ 1.5]. Exclusion Criteria: Patients who had been treated with cisplatin OR paclitaxel for any reason within 3 weeks prior to HIPEC. A history of HIPEC treatment
Sites / Locations
- Sun Yat-sen Memorial HospitalRecruiting
Arms of the Study
Arm 1
Experimental
Hyperthermic Intraperitoneal Paclitaxel Combined With Cisplatin
Patients with ovarian cancer receive hyperthermic intraperitoneal paclitaxel combined with a fixed dose of cisplatin (75mg/m2)